Martínez-Gutiérrez Laura, Rodriguez-Martin Inmaculada, Borrego-Yaniz Gonzalo, Kerick Martin, Salvarani Carlo, Hernández-Rodríguez José, Cid María Cinta, González-Gay Miguel Ángel, Morgan Ann W, Martín Javier, Ortiz-Fernández Lourdes, Márquez Ana
Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain.
Azienda USLIRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy.
Aging Dis. 2025 Aug 28. doi: 10.14336/AD.2025.0609.
Giant cell arteritis (GCA) is a complex inflammatory disease affecting individuals over 50 suggesting a strong link with aging-related immune and vascular changes. However, the precise mechanisms underlying this age-related susceptibility remain poorly understood. Considering the relevance of aging in GCA, genetic factors influencing biological aging markers, such as telomere shortening and epigenetic age acceleration (EAA), might also contribute to its development. This study investigated the shared genetic basis between GCA and these markers to enhance understanding of the role of aging in this vasculitis. Data from approximately 6.6 million variants obtained from previously published genome-wide association studies (GWASs) of GCA (3,498 cases and 15,550 controls), telomere length (472,174 individuals), and EAA (34,710 individuals) were meta-analysed using ASSET. Significant variants (p<5×10) were functionally annotated, and causal genes were prioritized using FUMA. Potential therapeutic candidates were identified through drug repurposing. This study identified 21 genetic variants shared between GCA and at least one aging marker. Two pleiotropic signals were annotated at PTPN22 and PLG, known risk factors for GCA, whereas the remainder represent potentially new susceptibility loci for this vasculitis. Several prioritized causal genes, such as SERPING1, SAR1B, SESN1, and SMC4, are involved in both inflammation and senescence, shedding light on the molecular pathways linking aging and GCA. Interestingly, expression levels of some of the prioritized genes PDE1B, ATXN2, and CNEP1R1, were dysregulated in immune cells from active patients. Drug repurposing analysis highlighted promising therapeutic candidates for GCA, including sulfasalazine, an anti-inflammatory agent, and investigational drugs targeting inflammatory pathways like NF-κB. These findings uncover significant genetic overlap between GCA and aging markers, offering insights into shared molecular pathways and potential new therapies targeting both inflammation and cellular senescence.
巨细胞动脉炎(GCA)是一种复杂的炎症性疾病,影响50岁以上的个体,提示与衰老相关的免疫和血管变化有密切联系。然而,这种与年龄相关易感性的精确机制仍知之甚少。考虑到衰老在GCA中的相关性,影响生物衰老标志物(如端粒缩短和表观遗传年龄加速(EAA))的遗传因素可能也有助于其发展。本研究调查了GCA与这些标志物之间的共同遗传基础,以增进对衰老在这种血管炎中作用的理解。使用ASSET对来自先前发表的GCA全基因组关联研究(GWAS)(3498例病例和15550例对照)、端粒长度(472174人)和EAA(34710人)的约660万个变异的数据进行了荟萃分析。对显著变异(p<5×10)进行功能注释,并使用FUMA对因果基因进行优先级排序。通过药物重新利用确定了潜在的治疗候选药物。本研究确定了GCA与至少一种衰老标志物之间共有的21个遗传变异。在已知的GCA风险因素PTPN22和PLG处注释了两个多效性信号,而其余的代表了这种血管炎潜在的新易感位点。几个优先级因果基因,如SERPING1、SAR1B、SESN1和SMC4,参与炎症和衰老,揭示了连接衰老和GCA的分子途径。有趣的是,一些优先级基因PDE1B、ATXN2和CNEP1R1的表达水平在活动期患者的免疫细胞中失调。药物重新利用分析突出了GCA有前景的治疗候选药物,包括抗炎药柳氮磺胺吡啶和靶向炎症途径如NF-κB的研究性药物。这些发现揭示了GCA与衰老标志物之间显著的遗传重叠,为共同的分子途径以及针对炎症和细胞衰老的潜在新疗法提供了见解。